News

bit.bio selected to join the ‘Future Fifty’ 2024 cohort as one of the UK’s most exciting technology companies.

bit.bio's CEO, envisions a new era of cell therapies, where cells themselves become intelligent drugs, precisely tailored to indiv...

bit.bio announce first project in multi-year collaboration agreement with The Michael J. Fox Foundation to generate products for r...

bit.bio's CEO, our cell programming approach and our products prominently covered in synthetic biology article.

Ginkgo Technology Network brings together over 25 partners across an array of capabilities including AI, genetic medicines, biolog...

Editor-in-Chief Carlos-Filipe Pereira interviews our CEO for the Reprogramming Stars series in the journal Cellular Reprogramming.

Award-winning journalist Daniel Levine and bit.bio CEO Mark Kotter discuss industrialised cell programming and its use in research...

Host Matt Pillar and bit.bio CEO Mark Kotter discuss the concept of programmable biology and how it's fuelling a new breed of biot...